Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04873895
Other study ID # UPCC03221
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date January 24, 2022
Est. completion date April 25, 2024

Study information

Verified date April 2024
Source Abramson Cancer Center at Penn Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Liver metastases are a leading cause of death among patients with metastatic colorectal cancer. Duration of disease control is short following 2nd-line or later systemic therapy. Liver-directed therapy such as TACE has a higher response rate and improves progression-free survival (PFS), but the benefit is still limited. Cancer cells escape ischemic cell death via autophagy and hypoxia-inducible factor (HIF) activation. We hypothesize that blocking autophagy and the vascular endothelial growth factor (VEGF) pathway will improve both response and PFS following TACE.


Description:

Subjects with liver-dominant colorectal cancer metastases failing at least one line of systemic therapy will receive 2 weeks of axitinib 5mg twice daily (BID) and HCQ 600 mg BID followed by lobar or segmental TACE monthly until the entire tumor burden is treated, then continue axitinib/HCQ until progression or intolerable toxicity. Response and hepatic progression-free survival (HPFS) will be assessed one month post-TACE, then every 3 months.


Recruitment information / eligibility

Status Terminated
Enrollment 5
Est. completion date April 25, 2024
Est. primary completion date April 25, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age 18 years or more. 2. Pathologically-verified diagnosis of colorectal adenocarcinoma. 3. Measurable metastasis to liver with at least one dimension = 1.0 cm. 4. Liver dominant metastases as judged by multidisciplinary team consensus review of cross-sectional imaging of the chest, abdomen and pelvis. 5. At least 2 weeks must have elapsed from the last dose of chemotherapy before starting HCQ and at least 4 weeks must have elapsed from the last dose of VEGF/VEGFR therapy prior to starting axitinib. 6. Subjects must be at least 2 weeks beyond prior radiotherapy or surgery, and have recovered from all therapy associated toxicities. 7. Eastern Cooperative Oncology Group (ECOG) Performance status must be 0-1 (see Appendix II). 8. Absolute granulocyte count > 1,500/ul, platelet count > 75,000/ul, International Normalized Ratio (INR) < 1.6 9. Serum creatinine < 2.0 mg/dl; serum bilirubin < 2.0 mg/dl. 10. Urine protein:creatinine ratio < 1 or 24-hour urine protein < 1 gm/day 11. Liver function Child-Pugh A 12. Competent and willing to provide informed consent 13. Patients of reproductive potential agree to use approved contraceptive methods per section 5.4 Exclusion Criteria: 1. Contraindications to angiography and selective visceral catheterization: 1. severe allergy or intolerance to contrast media not controllable with prophylaxis. 2. bleeding diathesis not correctable by usual forms of therapy. 3. severe peripheral vascular disease precluding catheterization. 2. Contraindications to hepatic artery embolization: 1. high risk of hepatic failure, indicated by the constellation of greater than 50% liver replacement by tumor, lactate dehydrogenase (LDH) >425 mU/ml, aspartate aminotransferase (AST) >100mU/ml. and bilirubin >2 mg/dl. 2. tumor volume >75% of total liver volume. 3. portal vein occlusion without hepatopetal collateral flow demonstrated by angiography; or portal hypertension with hepatofugal flow. 4. hepatic encephalopathy. 3. Prior hepatic arterial infusion chemotherapy or hepatic radiation therapy. Prior surgical resection or ablation of liver metastases is acceptable. 4. No more than two prior lines of systemic chemotherapy. 5. Pregnancy or lactation 6. Known allergic reactions to irinotecan, HCQ or axitinib 7. Allergy to contrast not mitigated by usual prophylaxis 8. Serious infection requiring intravenous therapy. 9. Known retinal disease 10. Poorly controlled hypertension, defined as a blood pressure > 150/100 at the time of enrollment. Patients with a preexisting hypertension must be on a stable anti-hypertensive regimen 11. History of abdominal fistula, gastrointestinal perforation, or serious non-healing wounds, ulcers, or bone fractures 12. Known New York Heart Association class II or greater congestive heart failure (defined as symptoms of fatigue, dyspnea, or other symptoms with ordinary physical activity) 13. Known untreated brain metastases. History of treated metastases off steroids allowed.

Study Design


Intervention

Drug:
Axitinib 5 MG
axitinib 5 mg po BID until progression or intolerance
Hydroxychloroquine Pill
hydroxychloroquine 600 mg po BID until progression or intolerance
Procedure:
trans arterial chemoembolization
segmental or lobar TACE at 4-8 week intervals until entire tummy burden is treated.

Locations

Country Name City State
United States Abramson Cancer Center Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Abramson Cancer Center at Penn Medicine Pfizer

Country where clinical trial is conducted

United States, 

References & Publications (4)

Chan SL, Yeo W, Mo F, Chan AWH, Koh J, Li L, Hui EP, Chong CCN, Lai PBS, Mok TSK, Yu SCH. A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma. Cancer. 2017 Oct 15;123(20):3977-3985. doi: 10.1002/cncr.30825. Epub 2017 Jun 22. — View Citation

Fiorentini G, Sarti D, Nani R, Aliberti C, Fiorentini C, Guadagni S. Updates of colorectal cancer liver metastases therapy: review on DEBIRI. Hepat Oncol. 2020 Jan 21;7(1):HEP16. doi: 10.2217/hep-2019-0010. — View Citation

Fiorentini G, Sarti D, Nardella M, Inchingolo R, Nestola M, Rebonato A, Guadagni S. Chemoembolization Alone or Associated With Bevacizumab for Therapy of Colorectal Cancer Metastases: Preliminary Results of a Randomized Study. In Vivo. 2020 Mar-Apr;34(2):683-686. doi: 10.21873/invivo.11824. — View Citation

Gade TPF, Tucker E, Nakazawa MS, Hunt SJ, Wong W, Krock B, Weber CN, Nadolski GJ, Clark TWI, Soulen MC, Furth EE, Winkler JD, Amaravadi RK, Simon MC. Ischemia Induces Quiescence and Autophagy Dependence in Hepatocellular Carcinoma. Radiology. 2017 Jun;283(3):702-710. doi: 10.1148/radiol.2017160728. Epub 2017 Mar 2. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Serious adverse event (SAE) rate SAE is scored by CTCAE v5 (G3 or higher) and the 2017 revision of the Society of Interventional Radiology (SIR) Complications Classification categories 3-5. 12 months
Secondary objective response rate in the liver complete and partial response rate by RECIST and modified RECIST 3 months
Secondary Hepatic progression-free survival Time from initiation of therapy to progression in the liver by RECIST, death from any cause, or last documented progression-free status. 12 months
Secondary Progression-free survival Time from initiation of therapy to progression anywhere by RECIST, death from any cause, or last documented progression-free status. 12 months
Secondary Overall survival Time from initiation of therapy to death or last follow-up alive 24 months
Secondary axitinib treatment intensity Weeks on axitinib therapy multiplied by percentage of initially prescribed dose 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04712292 - Effects of COVID-19 Pandemic on the Outcomes of Colorectal Cancer
Active, not recruiting NCT03775980 - CIRSE Emprint Microwave Ablation Registry
Recruiting NCT05155124 - Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC Phase 1
Recruiting NCT06050447 - Factors Affecting the Results of Treatment of Patients With Colorectal Cancer
Active, not recruiting NCT03993626 - A Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal Cancer Phase 1/Phase 2
Recruiting NCT06314971 - Predicting Local and Distant Recurrence in T1 Colorectal Cancer
Recruiting NCT06342440 - Early Detection of Advanced Adenomas and Colorectal Cancer
Recruiting NCT05853094 - Postoperative Effects of Different Enterostomy Approaches N/A
Recruiting NCT06200831 - Simultaneous vs. Staged Resection of Colorectal Cancer With Synchronous Liver Metastases N/A
Recruiting NCT02758951 - Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases Phase 2/Phase 3
Recruiting NCT03686254 - The Effects of RFA in Combination With Second-line Chemotherapy and Bevacizumab on Unresectable CRLM Phase 2/Phase 3
Recruiting NCT05278351 - Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC Phase 2
Completed NCT04002128 - Tracheal Colonization and Outcome After Major Abdominal Cancer Surgery N/A
Recruiting NCT06208371 - Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM Phase 3
Not yet recruiting NCT05129774 - Chemoradiotherapy Sequenced Radical Surgery for Colorectal Cancer With PALNM N/A
Completed NCT06410729 - Significance of Benign Lymph Node Enlargement in Colorectal Cancer
Completed NCT03507699 - Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer Phase 1
Active, not recruiting NCT03581890 - Socioeconomic Position in Acute Colorectal Cancer Surgery
Recruiting NCT05138094 - LIVACOR Trial: Minimally Invasive LIVer And Simultaneous COlorectal Resection N/A
Recruiting NCT03191110 - The COLON Study: Colorectal Cancer Cohort